2018年8月21日 · This report describes the first potent and selective inhibitor of any CerS isoform, facilitating the discovery of a physiological role for CerS1 in the regulation of mitochondrial function and ...

2019年7月1日 · CerS inhibition by FB1 triggers a “perfect storm” of perturbations in structural and signaling SLs that include: reduced formation of dihydroceramides, ceramides, and complex SLs; elevated Sa and So and their 1-phosphates, novel 1-deoxy-sphingoid bases; and alteration of additional lipid metabolites from interrelated pathways.

2024年9月5日 · Fumonisin B1 (FB 1) has been extensively studied as a potent inhibitor of eukaryotic CerSs. In this study, we characterize the inhibition mechanism of FB 1 on yeast CerS (yCerS) and determine the structures of both FB 1 -bound and N-acyl-FB 1 -bound yCerS.

2024年11月30日 · Farber disease (FD) is a rare lysosomal storage disease caused by a complete deficiency in acid ceramidase (ASAH1), an enzyme that breaks down ceramide into...

2023年3月1日 · The main toxic mechanism of FB1 is that FB1 competitively inhibits CerS, which ultimately disrupts sphingolipid metabolism and leads to changes in biomarkers (Sa/So ratio).

CerS inhibition by FB1 triggers a "perfect storm" of perturbations in structural and signaling SLs that include: reduced formation of dihydroceramides, ceramides, and complex SLs; elevated Sa and So and their 1-phosphates, novel 1-deoxy-sphingoid bases; and alteration of additional lipid metabolites from interrelated pathways.

2024年11月11日 · Here we used cryo-electron microscopy single-particle analysis to unravel the structure of the yeast CerS complex in both an active and a fumonisin B1-inhibited state. Our results reveal the...

Fumonisin B1 (FB1) is a well-known inhibitor of de novo sphingolipid biosynthesis, due to its ability to inhibit ceramide synthases (CerS) activity. In mammals, this toxin triggers broad clinical symptoms with multi-organ dysfunction such as hepatotoxicity or pulmonary edema.

2014年8月26日 · Fumonisin B1 (FB1) is a well-known inhibitor of de novo sphingolipid biosynthesis, due to its ability to inhibit ceramide synthases (CerS) activity. In mammals, this toxin triggers broad clinical symptoms with multi-organ dysfunction such as …

Fumonisins are structural analogs of sphingosine and potent inhibitors of ceramide synthases (CerSs); they disrupt sphingolipid metabolism and cause disease in plants and animals. Over the past three decades, researchers have used fumonisin B1 (FB1), the most common fumonisin, as a probe to investigate sphingolipid metabolism in yeast and animals.